Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 3.2 to 1.3.
Financials
Financial year 2025
NORDIC PHARMA from Antwerpen, company number BE0892926867, closed financial year 2025 with a result of € 387,245 after tax. For that financial year NORDIC PHARMA recorded a gross margin of € 647,877 and equity of € 232,812. Compared with financial year 2024, the result moved from € 228,703 to € 387,245. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 232,812
▲ € 387,245 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 387,245
▲ 69% vs 2024
Profit after tax over the fiscal year.
€ 129,566
▼ 63% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -519,915.
People and assets in 2025
1.3
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 158,106
▼ 27% vs 2024
€ 121,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 900,000
▼ 5% vs 2024
Loans from banks and other lenders, long and short.
€ 126,078
▲ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,736
▼ 77% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 484,688 | € 451,106 | € 552,546 | € 647,877 | ▲ 17% |
| Profit after taxes | € -51,882 | € -523,278 | € 228,703 | € 387,245 | ▲ 69% |
| Equity | € 140,141 | € -383,136 | € -154,433 | € 232,812 | ▲ € 387,245 |
| Total debts | € 935,492 | € 1,829,607 | € 1,292,327 | € 1,094,819 | ▼ 15% |
| Cash | € 154,607 | € 278,769 | € 353,968 | € 129,566 | ▼ 63% |
| Retained profit | € -612,586 | € -1,135,863 | € -907,160 | € -519,915 | ▲ € 387,245 |
| Bank debt | € 530,000 | € 680,000 | € 950,000 | € 900,000 | ▼ 5% |
| Balance sheet total | € 1,075,634 | € 1,446,471 | € 1,137,894 | € 1,327,631 | ▲ 17% |
| Employees (FTE) | 3.2 | 3.2 | 1.8 | 1.3 | ▼ 0.5 |
Key figures of NORDIC PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NORDIC PHARMA?
What happened at NORDIC PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Anders LOFGREN stepped down as director. NBB
- Charlotte PHELPS stepped down as director. NBB
- Graham CLARK stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 387,245 (▲ 69% vs 2024). Source: NBB ↗
- Anders LOFGREN became a director. NBB
- Charlotte PHELPS became a director. NBB
- Graham CLARK became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 51,882 loss in 2022 to € 387,245 profit in 2025.
Paid € 3,648 in corporate taxes since 2022.
Best year ever: 2025, with € 387,245 profit.
On average € 498,400 of value added per employee in 2025.
A new publication or filing at NORDIC PHARMA? We notify you, reason included.
Follow NORDIC PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Anders LOFGREN
Managing director
since 2023 · until 2027
Charlotte PHELPS
Director
since 2023 · until 2027
Graham CLARK
Director
since 2023 · until 2027
Establishments
Establishment units
Physical locations of this company
Uitbreidingstraat 84.3
2600 Antwerpen
Laarstraat 16
2610 Antwerpen
Active since 19 October 2007
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Website info
Features
Security
Network
Details
- Company number
- 0892.926.867
- VAT number
- BE 0892.926.867
- Registered office
- Uitbreidingstraat 84.3, 2600 Antwerpen
- Names & denominations
- NORDIC PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 October 2007
- Peppol
- Active · Active since 20 Apr 2026
- Contact
- nordicpharma.be
- Activities · NACE
Markt- en opinieonderzoek
Marktonderzoekbureaus
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied